Literature DB >> 32482753

PIKing the next therapeutic target in multiple myeloma.

Jessica L Caro1, Faith E Davies2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32482753      PMCID： PMC7271612          DOI： 10.3324/haematol.2020.248971

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.

Authors:  Sophia Gayle; Sean Landrette; Neil Beeharry; Chris Conrad; Marylens Hernandez; Paul Beckett; Shawn M Ferguson; Talya Mandelkern; Meiling Zheng; Tian Xu; Jonathan Rothberg; Henri Lichenstein
Journal:  Blood       Date:  2017-01-19       Impact factor: 22.113

2.  PIKfyve inhibition increases exosome release and induces secretory autophagy.

Authors:  Nina Pettersen Hessvik; Anders Øverbye; Andreas Brech; Maria Lyngaas Torgersen; Ida Seim Jakobsen; Kirsten Sandvig; Alicia Llorente
Journal:  Cell Mol Life Sci       Date:  2016-07-20       Impact factor: 9.261

Review 3.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

4.  MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

Authors:  Ya-Wei Qiang; Shiqiao Ye; Yu Chen; Amy F Buros; Ricky Edmonson; Frits van Rhee; Bart Barlogie; Joshua Epstein; Gareth J Morgan; Faith E Davies
Journal:  Blood       Date:  2016-10-28       Impact factor: 22.113

5.  Effect of autophagy on multiple myeloma cell viability.

Authors:  Bao Hoang; Angelica Benavides; Yijiang Shi; Patrick Frost; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

6.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

Review 7.  DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Authors:  Lauren I Aronson; Faith E Davies
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

8.  Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.

Authors:  L I Aronson; E L Davenport; F Mirabella; G J Morgan; F E Davies
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

Review 9.  From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Authors:  Francesca Gay; Monika Engelhardt; Evangelos Terpos; Ralph Wäsch; Luisa Giaccone; Holger W Auner; Jo Caers; Martin Gramatzki; Niels van de Donk; Stefania Oliva; Elena Zamagni; Laurent Garderet; Christian Straka; Roman Hajek; Heinz Ludwig; Herman Einsele; Meletios Dimopoulos; Mario Boccadoro; Nicolaus Kröger; Michele Cavo; Hartmut Goldschmidt; Benedetto Bruno; Pieter Sonneveld
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

10.  Identification of PIKfyve kinase as a target in multiple myeloma.

Authors:  Cecilia Bonolo de Campos; Yuan Xiao Zhu; Nikolai Sepetov; Sergei Romanov; Laura Ann Bruins; Chang-Xin Shi; Caleb K Stein; Joachim L Petit; Alysia N Polito; Meaghen E Sharik; Erin W Meermeier; Gregory J Ahmann; Ilsel D Lopez Armenta; Jonas Kruse; P Leif Bergsagel; Marta Chesi; Nathalie Meurice; Esteban Braggio; A Keith Stewart
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.